<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03238547</url>
  </required_header>
  <id_info>
    <org_study_id>URiSCAN_SNU_01</org_study_id>
    <nct_id>NCT03238547</nct_id>
  </id_info>
  <brief_title>Screening of Microalbuminuria Using a Semi-quantitative UACR Test</brief_title>
  <official_title>Accuracy of a Semi-quantitative Urine Albumin-to-creatinine Ratio Test as a Screening Tool for Microalbuminuria in Patients With Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      Microalbuminuria is an important biomarker for the development of diabetic nephropathy and
      cardiovascular complications. Since microalbuminuria is not easily detected on routine
      urinalysis, current guidelines recommend measuring spot urine albumin-to-creatinine ratio
      (uACR) annually in a patient with diabetes mellitus. While the standard method is
      quantitative measurement using turbidimetric immunoassay, it requires high cost and special
      laboratory equipment. This may be a hurdle that prevents screening for microalbuminuria in
      many patients with diabetes. Therefore, a semi-quantitative uACR test, which is rapid and
      inexpensive, could be used as a substitute to the current standard quantitative measurement.
      The investigators aimed to assess the diagnostic accuracy of a semi-quantitative urine
      albumin-to-creatinine ratio test, URiSCAN 2ACR, as a screening tool for microalbuminuria in
      patients with diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>18 Months</target_duration>
  <primary_outcome>
    <measure>Diagnostic Sensitivity and Specificity</measure>
    <time_frame>through study completion, an average of 18 months</time_frame>
    <description>Diagnostic Sensitivity and Specificity of URiSCAN 2ACR compared with standard method</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Diabetes</condition>
  <condition>Microalbuminuria</condition>
  <arm_group>
    <arm_group_label>diabetes</arm_group_label>
    <description>Diabetes patients with normal renal function and normal urinalysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>semi-quantitative urine albumin-to-creatinine ratio test</intervention_name>
    <description>measurement of urine albumin-to-creatinine ratio using URiSCAN 2ACR, a semi-quantitative urine albumin-to-creatinine ratio test</description>
    <arm_group_label>diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>standard quantitative spot urine albumin-to-creatinine ratio</intervention_name>
    <description>measurement of urine albumin-to-creatinine ratio using a standard turbidimetric immunoassay</description>
    <arm_group_label>diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        diabetic patients following Seoul National University Hospital
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diabetes

        Exclusion Criteria:

          -  microscopic hematuria

          -  pyuria

          -  urinary cast
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yaerim Kim, MD, PhD</last_name>
    <phone>82-10-5119-8805</phone>
    <email>yaerim86@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dong Ki Kim, MD, PhD</last_name>
    <phone>82-10-3711-0241</phone>
    <email>dkkim73@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Ki Kim, Prof</last_name>
      <phone>82-2-2072-2303</phone>
      <email>dkkim73@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dong Ki Kim, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2017</study_first_submitted>
  <study_first_submitted_qc>August 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2017</study_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Dong Ki Kim</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

